This is a summary of the European public assessment report (EPAR) for Zyclara. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Zyclara. For practical information about using Zyclara, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Zyclara is indicated for the topical treatment of clinically typical, non-hyperkeratotic, non-hypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.
Therapeutic Area (MeSH)
ATC Code
D06BB10
ATC Item
imiquimod
Pharmacotherapeutic Group
Antibiotics and chemotherapeutics for dermatological use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| imiquimod | N/A | 咪喹莫特 |
EMA Name
Zyclara
Medicine Name
Zyclara
Aliases
N/ANo risk management plan link.
